Immunome Says Varegacestat Reduced Symptoms in Phase 3 Desmoid Tumor Trial
Immunome presented results from a Phase 3 trial of varegacestat in desmoid tumors, reporting reduced symptom burden.
Immunome presented results from a Phase 3 trial of varegacestat in desmoid tumors, reporting reduced symptom burden.